Cargando…

Effect of administering subsequent immune checkpoint inhibition in cancer patients with prior COVID-19 infection

Detalles Bibliográficos
Autores principales:	Bi, Jianping, Wang, Sheng, Wang, Yajie, Yang, Dongqin, Verma, Vivek, Huang, Jing, Han, Guang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The British Infection Association. Published by Elsevier Ltd. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543776/ https://www.ncbi.nlm.nih.gov/pubmed/33039499 http://dx.doi.org/10.1016/j.jinf.2020.10.005

Ejemplares similares

Dosimetric Risk Factors for Acute Radiation Pneumonitis in Patients With Prior Receipt of Immune Checkpoint Inhibitors
por: Bi, Jianping, et al.
Publicado: (2022)

Does chemotherapy reactivate SARS-CoV-2 in cancer patients recovered from prior COVID-19 infection?
por: Bi, Jianping, et al.
Publicado: (2020)

Clinical outcomes of coronavirus disease 2019 (COVID‐19) in cancer patients with prior exposure to immune checkpoint inhibitors
por: Wu, Qiuji, et al.
Publicado: (2020)

Does multiple transfusion history necessitate additional cross matching evaluation prior to subsequent transfusions?
por: Sheshadri, Veena, et al.
Publicado: (2015)

The effects of B cell depletion on immune related adverse events associated with immune checkpoint inhibition
por: Risbjerg, Rasmus Strøm, et al.
Publicado: (2020)

Prior COVID-19 significantly reduces the risk of subsequent infection, but reinfections are seen after eight months
por: Breathnach, Aodhán Seán, et al.
Publicado: (2021)

Expression patterns of immune checkpoints in acute myeloid leukemia
por: Chen, Cunte, et al.
Publicado: (2020)

An immunomodulatory signature of responsiveness to immune checkpoint blockade therapy
por: Shen, Hongru, et al.
Publicado: (2020)

Comparing organ‐specific immune‐related adverse events for immune checkpoint inhibitors: A Bayesian network meta‐analysis
por: Li, Meichen, et al.
Publicado: (2021)

Immune checkpoint inhibitors: friend or foe for osteoporosis
por: Tang, Jun
Publicado: (2023)

Prevalence and clinical characterization of cancer patients with asymptomatic SARS-CoV-2 infection history
por: Bi, Jianping, et al.
Publicado: (2020)

The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors
por: Jin, Ying, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
por: Bylsma, Sophia, et al.
Publicado: (2022)

POLE/POLD1 mutation in non‐exonuclease domain matters for predicting efficacy of immune‐checkpoint‐inhibitor therapy
por: Chen, Yan‐Xing, et al.
Publicado: (2021)

Response letter: Letter to the editor regarding Wei W et al.: ‘‘Experience of the Hubei cancer hospital in Wuhan, China”
por: Bi, Jianping, et al.
Publicado: (2021)

Hepatocellular carcinoma and immunotherapy: Beyond immune checkpoint inhibitors
por: Abushukair, Hassan Mohammed, et al.
Publicado: (2022)

Life-threatening upper airway obstruction associated with prior radiotherapy
por: Singhal, Sanjay, et al.
Publicado: (2013)

Letter Regarding “Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma”
por: Wang, Yinhan, et al.
Publicado: (2022)

Rechallenge in Immune Checkpoint Inhibitors Associated Renal Tubular Acidosis
por: Shah, Chintan V., et al.
Publicado: (2023)

Immune-Checkpoint-Inhibitor-Induced Severe Autoimmune Encephalitis Treated by Steroid and Intravenous Immunoglobulin
por: Kim, Ahwon, et al.
Publicado: (2019)

Inactivating mutations in genes encoding for components of the BAF/PBAF complex and immune-checkpoint inhibitor outcome
por: Courtet, Kevin, et al.
Publicado: (2020)

Self-administered osteoporosis risk score
por: Wiwanitkit, Viroj
Publicado: (2011)

Prediction of major adverse cardiac events is the first critical task in the management of immune checkpoint inhibitor‐associated myocarditis
por: Xu, Yan, et al.
Publicado: (2022)

In vivo and in situ programming of tumor immunity by combining oncolytics and PD-1 immune checkpoint blockade
por: Bartee, Eric, et al.
Publicado: (2017)

Neoadjuvant immune checkpoint inhibitor plus chemotherapy in rare tracheal tumors
por: Jiang, Ben‐Yuan, et al.
Publicado: (2021)

Osteonecrosis of the jaw induced by immune checkpoint inhibitors: an urgent need for attention
por: Li, Xinya, et al.
Publicado: (2023)

Modulation of fatty acid synthase by ATR checkpoint kinase Rad3
por: Qiu, Shuwan, et al.
Publicado: (2019)

Assessment of administering antithrombosis in COVID-19 patients with acute hypoxemic respiratory failure
por: Wang, Ping, et al.
Publicado: (2021)

Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real‐world retrospective analysis
por: Zhou, Chengjing, et al.
Publicado: (2021)

Hypertensive diseases in pregnancy and subsequent lower risk of breast cancer: the common immune and antiangiogenic profile
por: Carbillon, L
Publicado: (2012)

Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas
por: Tsukita, Yoko, et al.
Publicado: (2019)

Immune checkpoint inhibitor-induced encephalitis with dostarlimab in two patients: Case series
por: Marzoughi, Sina, et al.
Publicado: (2021)

The intravenously administered palonosetron does not affect the spinal anesthesia
por: Kim, Myoung-Hun, et al.
Publicado: (2013)

Assessing adequacy of collateral foot circulation: A simple bedside test prior to lower extremity arterial cannulation
por: Kaushal, Ashutosh, et al.
Publicado: (2020)

Response to ‘The effect of PD-L1 testing on the cost-effectiveness of immune checkpoint inhibitors’
por: Ogale, S
Publicado: (2018)

The immune checkpoints storm in COVID‐19: Role as severity markers at emergency department admission
por: Avendaño‐Ortiz, José, et al.
Publicado: (2021)

Hypothyroidism-induced kidney dysfunction: an under-recognized phenomenon in patients on immune checkpoint inhibitors
por: Tan, Hui Zhuan, et al.
Publicado: (2022)

Influence of vaccination and prior immunity on the dynamics of Omicron BA.1 and BA.2 sub-variants
por: Dimeglio, Chloé, et al.
Publicado: (2022)

NICOLAS, DETERRED and KEYNOTE 799: focus on escalation of conventionally fractionated chemoradiotherapy by immune checkpoint inhibition in unresectable stage III non-small cell lung cancer
por: Manapov, Farkhad, et al.
Publicado: (2022)

The Promising Link Among Tumor Mutational Burden, Immune-Related Adverse Events, and Immune Checkpoint Inhibitors Efficacy in SCLC
por: Cortellini, Alessio
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uovl3cq2csj4t4dirk14lfks7c